Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 90, Issue 4, Pages 568-574Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2011.194
Keywords
-
Categories
Funding
- University of Maryland General Clinical Research Center [M01 RR 16500]
- General Clinical Research Centers
- National Center for Research Resources (NCRR)
- Baltimore Veterans Administration Geriatric Research and Education Clinical Center (GRECC)
- Sinai Hospital of Baltimore
- Amish community
- AstraZeneca
- Daiichi-Sankyo
- Bayer Healthcare
- Eli Lilly
- Portola Pharmaceuticals
- Haemonetics
- Pozen
- Sanofi-Aventis
- National Institutes of Health
- [NIH U01 GM074518]
- [U01 HL105198]
Ask authors/readers for more resources
A common functional variant in paraoxonase 1 (PON1), Q192R, was recently reported to be a major determinant of clopidogrel response. This variant was genotyped in 566 participants of the Amish Pharmacogenomics of Anti-Platelet Intervention (PAPI) study and in 227 percutaneous coronary intervention (PCI) patients. Serum paraoxonase activity was measured in a subset of 79 PAPI participants. PON1 Q192R was not associated with pre-or post-clopidogrel platelet aggregation in the PAPI study (P = 0.16 and P = 0.21, respectively) or the PCI cohort (P = 0.47 and P = 0.91, respectively). The Q192 allele was not associated with cardiovascular events (hazard ratio (HR) 0.46, 95% confidence interval (CI) 0.20-1.06; P = 0.07). No correlation was observed between paraoxonase activity and post-clopidogrel platelet aggregation (r(2) < 0.01, P = 0.78). None of 49 additional PON1 variants evaluated was associated with post-clopidogrel platelet aggregation. These findings do not support a role for PON1 as a determinant of clopidogrel response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available